David Altshuler, EVP, Global Research and CSO at VERTEX PHARMACEUTICALS INC / MA (VRTX), sold 12,796 shares at $296.85 ($3.8M) on 2023-02-14, disclosed to the SEC on 2023-02-16.
Seasonal sale ($3.8M) by EVP, Global Research and CSO — this insider has traded VRTX in February in at least three consecutive prior years. Pattern-driven, low signal.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $295.79 | 800 | $237K | 6.2% |
| 2 | $295.79 | 800 | $237K | 6.2% |
| 3 | $296.85 | 842 | $250K | 6.5% |
| 4 | $296.85 | 842 | $250K | 6.5% |
| 5 | $297.97 | 395 | $118K | 3.1% |
| 6 | $297.97 | 395 |
| $118K |
| 3.1% |
| 7 | $299.08 | 2,165 | $648K | 16.9% |
| 8 | $299.08 | 2,165 | $648K | 16.9% |
| 9 | $300.11 | 1,888 | $567K | 14.8% |
| 10 | $300.11 | 1,888 | $567K | 14.8% |
| 11 | $301.02 | 308 | $93K | 2.4% |
| 12 | $301.02 | 308 | $93K | 2.4% |
| Total | $298.70 avg | 12,796 | $3.8M | 100% |
| Filing → |
| VRTX | SELL | 2025-03-12 | $1.6M | — | Filing → |
| VRTX | SELL | 2025-03-05 | $1.6M | — | Filing → |
| VRTX | SELL | 2025-02-28 | $611K | — | Filing → |